Homocysteine a non-conventional risk factor for vasculopathic patients
Keywords:
Homocysteine; Vasculopathy; Ischaemic heart disease; Stroke; Deep vein thrombosis; Risk FactorAbstract
Research is underway and many other factors are being identified, including homocysteine (Hcy). Since 1990, there has been an exponential increase in the number of publications on Hcy and coronary artery disease, suggesting elevated plasma Hcy as an independent risk factor. As a result, this study was conducted to determine the prevalence of a new risk factor (homocysteine) in the general population (both young and old), as well as any differences in prevalence rates (if any) between young (less than 45 years of age) and elderly (more than 45 years of age) patients with vasculopathy. This was a case control study done in the cardiology unit of Bharti Hospital, Pune. All the patients diagnosed as cases of vasculopathies, especially IHD/Stroke/DVT (n =75) were enrolled as cases for the study, and healthy volunteers of the same age and gender matched (n =75) were enrolled as controls and subjected to the following inclusion and exclusion criteria. All cases and controls were assessed for their homocysteine level on day 0 of admission by using the MEIA/FPIA Technique on IMX, Abbott, USA. The mean homocysteine level was 23.2499 (12.2739) in cases vs. 13.24 (3.0912) in controls, with a statistically significant ‘p’ value by unpaired ‘t’ and MannWhitney statistics. Elevated Hcy levels above 15 mol/l were detected in 70% of cases and 22% of controls, respectively. On comparing homocysteine to individual vasculopathy, it was found that homocysteine was a more significant risk factor in IHD > stroke >DVT.
Downloads
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The journal allows the author(s) to hold the copyright without restrictions and will retain publishing rights without restrictions.
The submitted papers are assumed to contain no proprietary material unprotected by patent or patent application; responsibility for technical content and for protection of proprietary material rests solely with the author(s) and their organizations and is not the responsibility of the journal. The main (first/corresponding) author is responsible for ensuring that the article has been seen and approved by all the other authors. It is the responsibility of the author to obtain all necessary copyright release permissions for the use of any copyrighted materials in the manuscript prior to the submission.
What are my rights as an author?
It is important to check the policy for the journal to which you are submitting or publishing to establish your rights as
Author. Journal's standard policies allow the following re-use rights:
- The journal allows the author(s) to hold the copyright without restrictions.
- The journal allows the author(s) to obtain publishing rights without restrictions.
- You may do whatever you wish with the version of the article you submitted to the journal.
- Once the article has been accepted for publication, you may post the accepted version of the article on your own personal website, your department's website or the repository of your institution without any restrictions.
- You may not post the accepted version of the article in any repository other than those listed above (i.e. you may not deposit in the repository of another institution or a subject-matter repository) until 12 months after publication of the article in the journal.
- You may use the published article for your own teaching needs or to supply on an individual basis to research colleagues, provided that such supply is not for commercial purposes.
